Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Virginia Beach, Virginia 23462


Purpose:

The purpose of this study is to determine if patients initiating androgen deprivation therapy (ADT) for prostate cancer can be transitioned from degarelix acetate to leuprolide acetate after an initial three-month period without a rise in serum testosterone. The investigators expect testosterone will quickly and reliably reach castrate levels after initiation of ADT and will remain castrate during the transition, and there will be no "testosterone surge" after leuprolide injection.


Criteria:

Inclusion Criteria: - 18 years or older - Histologically confirmed adenocarcinoma of the prostate - Androgen deprivation therapy is indicated Exclusion Criteria: - Baseline screening serum testosterone <150ng/dL - Eastern Cooperative Oncology Group (ECOG) score > 2 - Diagnosed spinal or brain metastases - Hormonal manipulation within previous 6 months


NCT ID:

NCT01344564


Primary Contact:

Principal Investigator
Robert Given, MD
Urology of Virginia


Backup Contact:

N/A


Location Contact:

Virginia Beach, Virginia 23462
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.